Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease (original) (raw)
Article navigation
Meta-Analysis| May 02 2008
aThe Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital,
bThe Copenhagen Trial Unit, Center for Clinical Intervention Research, Institute of Preventive Medicine,
Search for other works by this author on:
cDepartment of Cardiology, Amager Hospital, Copenhagen University Hospital and
Search for other works by this author on:
dDepartment of Cardiology Y, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen,
Search for other works by this author on:
dDepartment of Cardiology Y, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen,
Search for other works by this author on:
eDepartment of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Hvidovre,
Search for other works by this author on:
fThe Heart Center, Department of Medicine B, Rigshospitalet, Copenhagen University Hospital, Copenhagen,
Search for other works by this author on:
gDepartment of Cardiology E, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg,
Search for other works by this author on:
hDepartment of Biostatistics, Institute of Public Health, Faculty of Health Sciences, University of Copenhagen, Copenhagen,
Search for other works by this author on:
eDepartment of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Hvidovre,
Search for other works by this author on:
fThe Heart Center, Department of Medicine B, Rigshospitalet, Copenhagen University Hospital, Copenhagen,
Search for other works by this author on:
iDepartment of Clinical Microbiology, Odense University Hospital, Odense,
Search for other works by this author on:
jDepartment of Cardiology S, Herlev Hospital, Copenhagen University Hospital, Herlev, and
Search for other works by this author on:
kStatens Serum Institut, Copenhagen, Denmark
Search for other works by this author on:
cDepartment of Cardiology, Amager Hospital, Copenhagen University Hospital and
Search for other works by this author on:
gDepartment of Cardiology E, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg,
Search for other works by this author on:
aThe Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital,
dDepartment of Cardiology Y, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen,
Search for other works by this author on:
Cardiology (2008) 111 (4): 280–287.
Citation
Christian Gluud, Bodil Als-Nielsen, Morten Damgaard, Jørgen Fischer Hansen, Stig Hansen, Olav H. Helø, Per Hildebrandt, Jørgen Hilden, Gorm Boje Jensen, Jens Kastrup, Hans Jørn Kolmos, Erik Kjøller, Inga Lind, Henrik Nielsen, Lars Petersen, Christian M. Jespersen; Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease. _Cardiology 1 October 2008; 111 (4): 280–287. https://doi.org/10.1159/000128994
Download citation file:
Abstract
Objectives: We have reported increased 2.6-year mortality in clarithromycin- versus placebo-exposed stable coronary heart disease patients, but meta-analysis of randomized trials in coronary heart disease patients showed no significant effect of antibiotics on mortality. Here we report the 6-year mortality of clarithromycin- versus placebo-exposed patients and updated meta-analyses. Methods: Centrally randomized, placebo controlled multicenter trial. All parties were blinded. Analyses were by intention to treat. Meta-analyses followed the Cochrane Collaboration methodology. Results: We randomized 4,372 patients with stable coronary heart disease to clarithromycin 500 mg (n = 2,172) or placebo (n = 2,200) once daily for 2 weeks. Mortality was followed through public register. Nine hundred and twenty-three patients (21.1%) died. Six-year mortality was significantly higher in the clarithromycin group (hazard ratio 1.21, 95% confidence interval 1.06–1.38). Adjustment for entry characteristics (sex, age, prior myocardial infarction, center, and smoking) did not change the results (1.18, 1.04–1.35). Addition of our data to that of other randomized trials on antibiotics for patients with coronary heart disease versus placebo/no intervention (17 trials, 25,271 patients, 1,877 deaths) showed a significantly increased relative risk of death from antibiotics of 1.10 (1.01–1.20) without heterogeneity. Conclusions: Our results stress the necessity to consider carefully the strength of the indication before administering antibiotics to patients with coronary heart disease.
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$45.00
1 Karger Article Bundle Token
$170
Rental
This article is also available for rental through DeepDyve. 